A disturbed metabolic pattern alone is discussed to promote arrhythmias and SCD [60,61] and may be a point of action for SGLT2 inhibitors, that demonstrated to stabilize an impaired state of energy consumption of the heart [18]. The gene discussed is SLC5A2; the disease is cardiac arrhythmia.